Use of the Peroxisome Proliferator-Activated Receptor (PPAR)  Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study

Author: Burstein H.J.  

Publisher: Springer Publishing Company

ISSN: 0167-6806

Source: Breast Cancer Research and Treatment, Vol.79, Iss.3, 2003-06, pp. : 391-397

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content